Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Haute Autorité de Santé. Tests in vitro de dépistage de l'infection tuberculeuse latente par détection de production d'interféron gamma. [Interferon-gamma release assays as in vitro screening tests for latent tuberculosis infection] Paris: Haute Autorité de Santé (HAS). 2015 Authors' objectives The aim of this report is to establish whether data from a critical analysis of good practice guidelines are coherent with the information in the application from the Caisse nationale d'assurance maladie des travailleurs salariés (CNAMTS [National Health Insurance fund for salaried workers]) and therefore support this application for the inclusion of IGRA tests on the list of procedures and services reimbursed by National Health Insurance. Authors' conclusions As there is consistency between the conclusions of the analysis of the guidelines and the information in the
application for including the tests, HAS considers that IGRA tests can be used for diagnosis in the following indications proposed by CNAMTS:
• in "migrant children aged under 15 years", subject to the following two additions:
- add the migrants' origin: "migrant children aged under 15 years coming from a region with high rates
of tuberculosis",
- specify that in children aged under five years, these tests should only be used following discussion with
clinical and laboratory staff, in view of the limited data currently available on using IGRA tests in these children;
• in HIV-positive patients, to screen for latent tuberculous infection (LTBI) as part of the initial assessment of their infection:
- with the option of repeating an IGRA test to check an uncertain or negative result obtained from initial
IGRA testing;
• to help with diagnosing tuberculosis disease in cases of extrapulmonary tuberculosis and with difficult diagnosis in children.
In addition, HAS agrees with the applicant regarding the need to include both the quantitative results and the
interpretation of IGRA tests in reports.
In accordance with the March 2015 road map, without a new assessment, HAS also renews its favourable opinion (issued in December 2006) on the indication for IGRA testing before starting treatment with TNF-alpha inhibitors.
INAHTA brief and checklist INAHTA brief and checklist Indexing Status Subject indexing assigned by CRD MeSH Humans; Interferon-gamma; Latent Tuberculosis; Tuberculin Test Country of organisation France English summary An English language summary is available. Address for correspondence French National Authority for Health, 2, avenue du Stade de France, Saint-Denis La Plaine, FR-93218 Paris France
Tel: +33 1 55 937188 Email: international.affairs@has-sante.fr AccessionNumber 32016000223 Date abstract record published 09/02/2016 |